Alivus Life Sciences Limited (NSE:ALIVUS)

Market Cap	122.70B
Revenue (ttm)	24.04B
Net Income (ttm)	4.96B
Shares Out	122.63M
EPS (ttm)	40.32
PE Ratio	24.82
Forward PE	21.31
Dividend	5.00 (0.48%)
Ex-Dividend Date	n/a

Volume	24,179
Average Volume	78,662
Open	1,008.10
Previous Close	1,019.80
Day's Range	1,008.10 - 1,034.40
52-Week Range	850.00 - 1,251.00
Beta	0.12
RSI	41.94
Earnings Date	Jul 23, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 2,014
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALIVUS

Financial Performance

In 2024, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.